Ventilator-Induced Lung Injury (VILI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Ventilator-Induced Lung Injury (VILI) Market Outlook

Thelansis’s “Ventilator-Induced Lung Injury (VILI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ventilator-Induced Lung Injury (VILI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ventilator-Induced Lung Injury (VILI) Overview

Ventilator-Induced Lung Injury (VILI) could occur during invasive and non-invasive ventilation and could significantly contribute to the morbidity and mortality of critically ill patients. Though mechanical ventilation can injure both normal and diseased lungs, the latter will suffer far more severe damage due to higher microscale stresses. The terms ventilator-induced lung injury (VILI) and ventilator-associated lung injury (VALI) have been used interchangeably (VALI). The most common mechanisms of ventilator-induced lung injury are alveolar overdistention (volutrauma), barotrauma, atelectotrauma, and inflammation (biotrauma). Other attributed mechanisms include adverse heart-lung interactions, deflation-related, and effort-induced injuries. Even though both strategies result in identical high levels of end-inspiratory pressure and alveolar distension, ventilation with high tidal volume and low or zero PEEP appears to be more harmful than ventilation with low tidal volume and high PEEP. Ventilation of isolated lavaged rat lungs with small tidal volumes (5–6 ml/kg) and low or zero PEEP caused lung injury that increasing PEEP levels could mitigate.

• The incidence of Ventilator-induced lung injury (VILI) varies from 41 to 57 cases per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: